Sonoma Pharmaceuticals, Inc. (SNOA)
NASDAQ: SNOA · Real-Time Price · USD
4.170
-0.080 (-1.88%)
At close: Oct 8, 2025, 4:00 PM EDT
4.100
-0.070 (-1.68%)
After-hours: Oct 8, 2025, 4:50 PM EDT
Sonoma Pharmaceuticals Revenue
Sonoma Pharmaceuticals had revenue of $4.01M in the quarter ending June 30, 2025, with 18.40% growth. This brings the company's revenue in the last twelve months to $14.91M, up 17.43% year-over-year. In the fiscal year ending March 31, 2025, Sonoma Pharmaceuticals had annual revenue of $14.29M with 12.19% growth.
Revenue (ttm)
$14.91M
Revenue Growth
+17.43%
P/S Ratio
0.41
Revenue / Employee
$1,864,000
Employees
8
Market Cap
6.88M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 14.29M | 1.55M | 12.19% |
Mar 31, 2024 | 12.74M | -537.00K | -4.05% |
Mar 31, 2023 | 13.27M | 644.00K | 5.10% |
Mar 31, 2022 | 12.63M | -6.00M | -32.21% |
Mar 31, 2021 | 18.63M | 701.00K | 3.91% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
SNOA News
- 1 day ago - Sonoma Pharmaceuticals Expands Market Reach with FDA Cosmetic Product Facility Registration and Microcyn-Based Cosmetic Product Listing Under MoCRA - Accesswire
- 13 days ago - Sonoma Pharmaceuticals to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 - Accesswire
- 6 weeks ago - National Psoriasis Foundation Awards Seal of Recognition to Sonoma Pharmaceuticals for Reliefacyn Advanced - Accesswire
- 2 months ago - Sonoma Pharmaceuticals Announces Launch of Diaper Rash Product in Walmart and other U.S. Chains - Accesswire
- 2 months ago - Sonoma Pharmaceuticals Reports First Fiscal Quarter 2026 Financial Results - Accesswire
- 4 months ago - Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2025 Financial Results - Accesswire
- 6 months ago - Sonoma Pharmaceuticals Announces Registration of Acne Products in the United Kingdom and Launch of the Products in Leading U.K. Pharmacy Chain - Accesswire
- 7 months ago - Sonoma Pharmaceuticals Secures Extensive U.K. Regulatory Clearances of Key Wound Care and Dermatology Products by the Medicines & Healthcare Products Regulatory Agency (MHRA) - Accesswire